Download PDF
Adipositas - Ursachen, Folgeerkrankungen, Therapie 2021; 15(01): 21-27
DOI: 10.1055/a-1325-7517
Review

Adipositas und HFpEF – Henne oder Ei?

The Importance of HFpEF in Patients with Obesity
Karl-Patrik Kresoja
1   Universitätsklinik für Kardiologie, Herzzentrum Leipzig, Leipzig, Germany
,
Karl-Philipp Rommel
1   Universitätsklinik für Kardiologie, Herzzentrum Leipzig, Leipzig, Germany
,
Holger Thiele
1   Universitätsklinik für Kardiologie, Herzzentrum Leipzig, Leipzig, Germany
,
Philipp Lurz
1   Universitätsklinik für Kardiologie, Herzzentrum Leipzig, Leipzig, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Herzinsuffizienz mit erhaltener Pumpfunktion (HFpEF) ist wahrscheinlich eine der am häufigsten übersehenen Ursachen für das Vorliegen einer Belastungsdyspnoe bei Patienten mit Adipositas. Patienten mit Adipositas-assoziierter HFpEF machen bis zu 80 % aller HFpEF Patienten aus, und eine individualisierte Therapie für diese Patientengruppe zu finden ist von größter Wichtigkeit. Patienten mit Adipositas-assoziierter HFpEF sind gekennzeichnet durch eine progressive Expansion und Umwandlung des vor allem epikardialen Fettgewebes, einer Erhöhung des Plasmavolumens, einer verstärkten lokalen und systemischen Inflammation sowie einer ausgeprägten myokardialen Fibrose. Diese Veränderungen münden in einer ausgeprägten Belastungsintoleranz, Anfälligkeit für Volumenänderungen sowie einer sich intensivierenden Kaskade von Komorbiditäten. Individualisierte Therapien zur Behandlung der Adipositas-assoziierten HFpEF sind auf dem Weg und könnten erstmalige Erfolge bei der Behandlung des heterogenen HFpEF-Syndroms bringen.

Abstract

Heart failure with preserved ejection fraction (HFpEF) is likely one of the most underdiagnosed causes of exertional dyspnea in patients with obesity. Patients with HFpEF and obesity make up approximately 80 % of all HFpEF patients and identifying a tailored therapy for this population is of utmost importance. Patients with HFpEF and obesity show characteristic pathophysiological features that are marked by expanding and dysfunctional adipose tissue, especially in the epicardial region, plasma volume expansion, enhanced local and systemic inflammation, as well as increased myocardial fibrosis. These changes lead to extensive intolerance to physical exertion, susceptibility to increased preload, as well as an intensifying burden of co-morbidities. Individualized treatment approaches for patients with HFpEF and obesity are being developed and might provide effective therapies for the heterogeneous HFpEF syndrome for the first time.

Schlüsselwörter

Adipositas - HFpEF - Inflammation - Fibrose

Key words

Obesity - HFpEF - inflammation - fibrosis


Publication History

Article published online:
12 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Packer M. The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range. Eur J Heart Fail 2019; 21: 156-162.
    CrossrefPubMedSearch in Google Scholar
  • 2 Packer M. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. Circulation 2018; 137: 1614-1631.
    CrossrefPubMedSearch in Google Scholar
  • 3 Kenchaiah S, Evans JC, Levy D. et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
    CrossrefPubMedSearch in Google Scholar
  • 4 Reddy YNV, Carter RE, Obokata M. et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation 2018; 138: 861-870.
    CrossrefPubMedSearch in Google Scholar
  • 5 Haass M, Kitzman DW, Anand IS. et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: Results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-331.
    CrossrefPubMedSearch in Google Scholar
  • 6 Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020; 17: 559-573.
    CrossrefPubMedSearch in Google Scholar
  • 7 Obokata M, Reddy YNV, Pislaru SV. et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation 2017; 136: 6-19.
    CrossrefPubMedSearch in Google Scholar
  • 8 Wang Q, Wu HT. Cells in Adipose Tissue: Critical Players in Immunometabolism. Front Immunol 2018; 9: 2509.
    CrossrefPubMedSearch in Google Scholar
  • 9 Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J Am Coll Cardiol 2018; 71: 2360-2372.
    CrossrefPubMedSearch in Google Scholar
  • 10 Packer M. Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. Eur J Heart Fail 2020; 22: 214-227.
    CrossrefPubMedSearch in Google Scholar
  • 11 Chu C-Y, Lee W-H, Hsu P-C. et al. Association of Increased Epicardial Adipose Tissue Thickness With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation. Med (Baltimore) 2016; 95: e2874.
    CrossrefPubMedSearch in Google Scholar
  • 12 van Woerden G, Gorter TM, Westenbrink BD. et al. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. Eur J Heart Fail 2018; 20: 1559-1566.
    CrossrefPubMedSearch in Google Scholar
  • 13 Klein S, Fontana L, Young VL. et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350: 2549-2557.
    CrossrefPubMedSearch in Google Scholar
  • 14 Reddy YNV, Anantha-Narayanan M, Obokata M. et al. Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis. JACC Heart Fail 2019; 7: 678-687.
    CrossrefPubMedSearch in Google Scholar
  • 15 Koepp KE, Obokata M, Reddy YNV. et al. Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2020; 8: 657-666.
    CrossrefPubMedSearch in Google Scholar
  • 16 Rommel K-P, Roeder MV, Oberueck C. et al. Load-Independent Systolic and Diastolic Right Ventricular Function in Heart Failure With Preserved Ejection Fraction as Assessed by Resting and Handgrip Exercise Pressure-Volume Loops. Circ Heart Fail 2018; 11: e004121.
    CrossrefPubMedSearch in Google Scholar
  • 17 Nakamura K, Fuster JJ, Walsh K. Adipokines: A link between obesity and cardiovascular disease. J Cardiol 2014; 63: 250-259.
    CrossrefPubMedSearch in Google Scholar
  • 18 Packer M, Kitzman DW. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2. JACC Heart Fail 2018; 6: 633-639.
    CrossrefPubMedSearch in Google Scholar
  • 19 Dornfeld LP, Maxwell MH, Waks A. et al. Mechanisms of hypertension in obesity. Kidney Int Suppl 1987; 22: S254-8
    PubMedSearch in Google Scholar
  • 20 Huby A-C, Antonova G, Groenendyk J. et al. Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. Circulation 2015; 132: 2134-2145.
    CrossrefPubMedSearch in Google Scholar
  • 21 Hirata A, Maeda N, Nakatsuji H. et al. Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochem Biophys Res Commun 2012; 419: 182-187.
    CrossrefPubMedSearch in Google Scholar
  • 22 Edelmann F, Wachter R, Schmidt AG. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791.
    CrossrefPubMedSearch in Google Scholar
  • 23 Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H. et al. Fibrosis and cardiac function in obesity: A randomised controlled trial of aldosterone blockade. Heart 2013; 99: 320-326.
    CrossrefPubMedSearch in Google Scholar
  • 24 Anand IS, Claggett B, Liu J. et al. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. JACC Heart Fail 2017; 5: 241-252.
    CrossrefPubMedSearch in Google Scholar
  • 25 Voors AA, Kremer D, Geven C. et al. Adrenomedullin in heart failure: Pathophysiology and therapeutic application. Eur J Heart Fail 2019; 21: 163-171.
    CrossrefPubMedSearch in Google Scholar
  • 26 JJV M, Packer M, Desai AS. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
    CrossrefPubMedSearch in Google Scholar
  • 27 Solomon SD, JJV M, Anand IS. et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019; 381: 1609-1620.
    CrossrefPubMedSearch in Google Scholar
  • 28 Obokata M, Kane GC, Reddy YNV. et al. Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. Circulation 2017; 135: 825-838.
    CrossrefPubMedSearch in Google Scholar
  • 29 Kitzman DW, Brubaker P, Morgan T. et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2016; 315: 36-46.
    CrossrefPubMedSearch in Google Scholar
  • 30 Williams DM, Evans M. Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?. Diabetes Ther 2020; 11: 2207-2219.
    CrossrefPubMedSearch in Google Scholar
  • 31 Zannad F, Ferreira JP, Pocock SJ. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819-829.
    CrossrefPubMedSearch in Google Scholar